Ronald L. Green, M.D.
Dr. Green earned an M.D. and completed his residency at Wayne State University. He completed a fellowship in ophthalmic diagnostic ultrasound at the University of Iowa. Dr. Green has been Medical Director for the Doheny Eye Institute's Ultrasound Laboratory for the past ten years. He is the author of numerous papers and a major textbook on this subject. Dr. Green is now one of the most prominent ocular ultrasound experts in the world, and his recent comprehensive text is a classic in the field. He has participated in studies involving ocular trauma, intraocular tumors, orbital tumors and biometry for intraocular lens calculations. Dr. Green is a Professor at the USC Keck School of Medicine.

A. Linn Murphree, M.D.
Dr. Murphree earned an M.D. from Baylor College of Medicine. He completed three fellowships: one at the University of Copenhagen, another at Baylor College of Medicine, and the third at Wilmer Ophthalmological Institute, Johns Hopkins Hospital. Dr. Murphree is a Professor of Ophthalmology and Pediatrics at the USC Keck School of Medicine and leads the development of a world-class Ocular Oncology Service at Childrens Hospital of Los Angeles and at the Doheny Eye Institute. Dr. Murphree and his colleagues have also developed new protocols for the treatment of retinoblastoma. He co-chairs the Retinoblastoma Study (RBS), a planned international multicenter clinical trial.

Narsing A. Rao, M.D.
Dr. Rao earned an M.D. from Osmania University. He completed two residencies, one in pathology and one in ophthalmology at the Georgetown University Medical Center. He completed his fellowship in ophthalmic pathology at the Armed Forces Institute of Pathology. Dr. Rao is Director of the Inflammation, Uveitis, and AIDS Service and Director of the A. Ray Irvine, Jr., Ophthalmic Pathology Laboratory at Doheny, which is the cornerstone of the teaching program for the residents. Dr. Rao is involved in both the research aspects and clinical treatment of a broad range of inflammatory ocular diseases and tumors. Specialized medical and surgical clinical protocols are utilized to treat resistant cases of uveitis. The special drug regimen includes the use of cyclosporine, cytoxan and other immunosuppressives.